Our Portfolio

Thank you to the innovators who advance human health, each following their unique inspiration and insights, collectively rolling back the many diseases that weigh on all our lives and contributing to the knowledge that will enable further progress.

Private Investments
  • AAV gene therapies for Friedreich’s ataxia and other rare diseases

    Visit Site
  • First-in-class immunotherapies for autoimmune diseases and cancer

    Visit Site
  • Proteomics platform and small molecule inhibitors for ovarian cancer and other cancers

    Visit Site
  • Cryoablation catheters for cardiac arrhythmias

    Visit Site
  • Antibody-drug conjugates engineered to increase cell uptake for treatment of cancers

    Visit Site
  • Blood tests for early detection of cancer and other serious diseases

    Visit Site
  • Engineered AAV capsids, promoters, and manufacturing processes for next-gen gene therapies

    Visit Site
  • Natural product derivatives to protect crops from weeds, diseases, and insects

    Visit Site
  • Protein therapies for NASH, severe hypertriglyceridemia, and other cardiometabolic diseases

    Visit Site
  • Personalized T-cell therapies for non-small cell lung cancer and other cancers

    Visit Site
  • Small molecule inhibitors for rheumatoid arthritis and other immuno-inflammatory diseases

    Visit Site
  • Antibody targeting amyloid beta oligomers, a key pathogenic driver of Alzheimer's disease

    Visit Site
  • Antibody therapies for COVID-19 and other respiratory diseases

    Visit Site
  • Enzyme therapies to correct chemical imbalances for rare metabolic diseases

    Visit Site
  • Inhaled imatinib to target disease drivers of pulmonary arterial hypertension

    Visit Site
  • Palforzia allergen powder to manage peanut allergy and Zenpep pancreatic enzyme replacement therapy

    Visit Site

Information listed is as of August 01, 2022. The Crossover/Venture Investments tab reflects private companies that currently are in RA Capital’s portfolio in an open side pocket. If a company becomes public or is acquired by a third-party acquirer, it instead will be reflected under the Investments Acquired/IPO’d tab above. If a company is dissolved or redeems RA Capital’s investment, or another investor in a company purchases RA Capital‘s investment, such company will be removed from this website.

Notwithstanding the foregoing, certain private companies are not illustrated (1) because of confidentiality restrictions or arrangements or (2) because, to the best of RA Capital’s knowledge, such company does not have a logo or active website. References, either general or specific, to securities and/or issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. The earliest illustrated Crossover/Venture Investment occurred in February 2012. RA Capital makes no representations, and it should not be assumed, that past investment selection is necessarily indicative of future investment selection or performance.